Search

In Stock

Pharmacotherapeutics for Advanced Practice Nurse Prescribers Fifth Edition Test Bank

Instant delivery only

  • Chapters: 56
  • Format: PDF 
  • ISBN-13: 978-0803669260
  • ISBN-10: 0803669267
  • Publisher‎F.A. Davis Company; Fifth edition
  • Authors: by Teri Moser Woo, Marylou V. Robinson

Original price was: $90.00.Current price is: $18.10.

SKU:tb1001622

Pharmacotherapeutics for Advanced Practice Nurse Prescribers Fifth Edition Test Bank

Table of Contents

1. The Role of the Nurse Practitioner as Prescriber
2. Review of the Basic Principles of Pharmacology
3. Rational Drug Selection
4. Legal and Professional Issues in Prescribing
5. Adverse Drug Reactions
6. An Introduction to Pharmacogenetics
7. Nutrition and Neutraceuticals
8. Herbal Therapies and Cannabis
9. Information Technology and Pharmacotherapeutics
10. Pharmacoeconomics
UNIT II.?PHARMACOTHERAPEUTICS WITH SINGLE DRUGS
11. Drugs Affecting the Autonomic Nervous System
12. Drugs Affecting the Central Nervous System
13. Drugs Affecting the Cardiovascular and Renal Systems
14. Drugs Affecting the Respiratory System
15. Drugs Affecting the Hematological System
16. Drugs Affecting the Immune System
17. Drugs Affecting the Gastrointestinal System
18. Drugs Affecting the Endocrine System: Pancreatic Hormones and Antidiabetic Drugs
19. Drugs Affecting the Endocrine System: Pituitary, Thyroid, and Adrenal Drugs
20. Drugs Affecting the Reproductive System
21. Drugs Affecting the Bones and Joints
22. Drugs Affecting the Integumentary System
23. Drugs Used to Treat Bacterial Infections
24. Drugs Used to Treat Viral, Fungal, and Protozoal Infections
25. Drugs Used to Treat Inflammatory Processes
26. Drugs Used to Treat Eye and Ear Disorders
UNIT III.?PHARMACOTHERAPEUTICS WITH MULTIPLE DRUGS
27. Alcohol and Drug Addiction
28. Anemia
29. Angina
30. Anxiety and Depression
31. Attention Deficit Hyperactivity Disorder
32. Asthma and Chronic Obstructive Pulmonary Disease
33. Contraception
34. Dermatological Conditions
35. Diabetes Management
36. Gastroesophageal Reflux and Peptic Ulcer Disease
37. Headaches
38. Heart Failure
39. Human Immunodeficiency Virus Disease and Acquired Immunodeficiency Syndrome
40. Hormone Replacement Therapy
41. Hyperlipidemia
42. Hypertension
43. Hyperthyroidism and Hypothyroidism
44. Pain Management: Acute and Chronic Pain
45. Pneumonia
46. Tobacco Cessation
47. Sexually Transmitted Diseases and Vaginitis
48. Tuberculosis
49. Upper Respiratory Infection, Pharyngitis, Sinusitis, Otitis Media, and Otitis Externa
50. Urinary Tract Infection
UNIT IV.?SPECIAL DRUG TREATMENT CONSIDERATIONS
51. Women as Patients
52. Men as Patients
53. Pediatric Patients
54. Transgendered Clients as Patients
55. Geriatric Patients
Appendix A: New Drug Development
INDEX

Chapter 1 Issues for the Practitioner in Drug Therapy

MULTIPLE CHOICE
1. Nurse practitioner prescriptive authority is regulated by:
A. The National Council of State Boards of Nursing
B. The U.S. Drug Enforcement Administration
C. The State Board of Nursing for each state
D. The State Board of Pharmacy
ANS: C PTS: 1
2. Physician Assistant (PA) prescriptive authority is regulated by:
A. The National Council of State Boards of Nursing
B. The U.S. Drug Enforcement Administration
C. The State Board of Nursing
D. The State Board of Medical Examiners
ANS: D PTS: 1
3. Clinical judgment in prescribing includes:
A. Factoring in the cost to the patient of the medication prescribed
B. Always prescribing the newest medication available for the disease process
C. Handing out drug samples to poor patients
D. Prescribing all generic medications to cut costs
ANS: A PTS: 1
4. Criteria for choosing an effective drug for a disorder include:
A. Asking the patient what drug they think would work best for them
B. Consulting nationally recognized guidelines for disease management
C. Prescribing medications that are available as samples before writing a prescription
D. Following U.S. Drug Enforcement Administration (DEA) guidelines for
prescribing
ANS: B PTS: 1
5. Nurse practitioner practice may thrive under health-care reform due to:
A. The demonstrated ability of nurse practitioners to control costs and improve patient
outcomes
B. The fact that nurse practitioners will be able to practice independently
C. The fact that nurse practitioners will have full reimbursement under health-care
reform
D. The ability to shift accountability for Medicaid to the state level
ANS: A PTS: 1Chapter 2.Pharmacokinetic Basis of Therapeutics and Pharmacodynamic
MULTIPLE CHOICE
1. A patient’s nutritional intake and lab work reflects hypoalbuminemia. This is critical to
prescribing because:
A. Distribution of drugs to target tissue may be affected
B. The solubility of the drug will not match the site of absorption
C. There will be less free drug available to generate an effect
D. Drugs bound to albumin are readily excreted by the kidney
ANS: A PTS: 1
2. Drugs that have a significant first-pass effect:
A. Must be given by the enteral (oral) route only
B. Bypass the hepatic circulation
C. Are rapidly metabolized by the liver and may have little if any desired action
D. Are converted by the liver to more active and fat-soluble forms
ANS: C PTS: 1
3. The route of excretion of a volatile drug will likely be:
A. The kidneys
B. The lungs
C. The bile and feces
D. The skin
ANS: B PTS: 1
4. Medroxyprogesterone (Depo Provera) is prescribed IM to create a storage reservoir of the
drug. Storage reservoirs:
A. Assure that the drug will reach its intended target tissue
B. Are the reason for giving loading doses
C. Increase the length of time a drug is available and active
D. Are most common in collagen tissues
ANS: C PTS: 1
5. The NP chooses to give cephalexin every 8 hours based on knowledge of the drug’s:
A. Propensity to go to the target receptor
B. Biological half-life
C. Pharmacodynamics
D. Safety and side effects
ANS: B PTS: 1
6. Azithromycin dosing requires the first day’s dose be twice those of the other 4 days of the
prescription. This is considered a loading dose. A loading dose:
A. Rapidly achieves drug levels in the therapeutic range
B. Requires four to five half-lives to attain
C. Is influenced by renal function

D. Is directly related to the drug circulating to the target tissues
ANS: A PTS: 1
7. The point in time on the drug concentration curve that indicates the first sign of a therapeutic
effect is the:
A. Minimum adverse effect level
B. Peak of action
C. Onset of action
D. Therapeutic range
ANS: C PTS: 1
8. Phenytoin requires a trough level be drawn. Peak and trough levels are done:
A. When the drug has a wide therapeutic range
B. When the drug will be administered for a short time only
C. When there is a high correlation between the dose and saturation of receptor sites
D. To determine if a drug is in the therapeutic range
ANS: D PTS: 1
9. A laboratory result indicates the peak level for a drug is above the minimum toxic
concentration. This means that the:
A. Concentration will produce therapeutic effects
B. Concentration will produce an adverse response
C. Time between doses must be shortened
D. Duration of action of the drug is too long
ANS: B PTS: 1
10. Drugs that are receptor agonists may demonstrate what property?
A. Irreversible binding to the drug receptor site
B. Up-regulation with chronic use
C. Desensitization or down-regulation with continuous use
D. Inverse relationship between drug concentration and drug action
ANS: C PTS: 1
11. Drugs that are receptor antagonists, such as beta blockers, may cause:
A. Down-regulation of the drug receptor
B. An exaggerated response if abruptly discontinued
C. Partial blockade of the effects of agonist drugs
D. An exaggerated response to competitive drug agonists
ANS: B PTS: 1
12. Factors that affect gastric drug absorption include:
A. Liver enzyme activity
B. Protein-binding properties of the drug molecule
C. Lipid solubility of the drug
D. Ability to chew and swallow
ANS: C PTS: 1

Reviews

There are no reviews yet.

Write a review

Your email address will not be published. Required fields are marked *

Back to Top
Product has been added to your cart